Vasculitis
Conditions
Keywords
vasculitis, ANCA, mycophenolate mofetil, cyclophosphamide, Anti neutrophil cytoplasm antibody associated vasculitis
Brief summary
The purpose of this study is to investigate whether mycophenolate mofetil is effective as treatment for new cases of ANCA associated vasculitis.
Detailed description
There is a clear need for improved therapy in ANCA associated vasculitis where current treatments are toxic and contribute to poor outcomes. Conventional therapy combines cyclophosphamide with prednisolone but is associated with severe adverse events in 35%, early mortality, malignancy and infertility. Mycophenolate mofetil (MMF) is a newer immunosuppressive drug which has superior efficacy to azathioprine in solid organ transplantation. MMF is an effective alternative to cyclophosphamide in lupus nephritis. Open label studies and retrospective surveys point to the efficacy and low toxicity of MMF in vasculitis. We hypothesise that MMF not be less effective than cyclophosphamide for remission induction in AASV. 140 new patients will be randomised to MMF 3g/day or a European consensus intravenous cyclophosphamide regimen, with the same prednisolone dosing. Following a six month induction course all patients will receive consensus remission maintenance treatment with azathioprine and prednisolone. The primary end-point will be remission rate by six months, secondary end-points include relapse rate at 18 months and safety. The trial will be conducted in 10 countries by members of the European Vasculitis Study Group (EUVAS). The trial duration will be 42 months (24 months recruitment, 18 months follow up).
Interventions
DRUGmycophenolate mofetil
2-3g/day for 3-6 months, in tablet, capsule or liquid form
DRUGcyclophosphamide
intravenous cyclophosphamide, 15mg/kg with dose reductions according to age and renal function, for 3-6 months (6-10 doses total)
Sponsors
Aspreva Pharmaceuticals
Vifor Pharma
Cambridge University Hospitals NHS Foundation Trust
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
Inclusion (requires all): * New diagnosis of AASV (WG or MPA) (within the previous six months) * Active disease (defined by at least one major or three minor BVAS 2003 items, see appendix 1) * ANCA positivity (c-ANCA and PR3-ANCA or p-ANCA and MPO-ANCA) or histology confirming active vasculitis from any organ (see appendix ) * Written informed consent
Exclusion criteria
* Previous treatment with: * MMF: more than two weeks ever. * Cyclophosphamide: more than two weeks daily oral or more than 1 pulse of IV CYC (15mg/kg) * Rituximab or high dose intravenous immunoglobulin within the last twelve months * Active infection (including hepatitis B, C, HIV and tuberculosis). * Known hypersensitivity to MMF, AZA or CYC. * Cancer or an individual history of cancer (other than resected basal cell skin carcinoma). * Females who are pregnant, breast feeding, or at risk of pregnancy and not using a medically acceptable form of contraception. * Any condition judged by the investigator that would cause the study to be detrimental to the patient. * Any other multi-system autoimmune disease including Churg Strauss angiitis, SLE, anti GBM disease and cryoglobulinaemia.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Remission rates at 6 months | 6 months | Assessed by BVAS score of zero on 2 consecutive assessments |
Countries
United Kingdom
Outcome results
None listed